Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)
Key Highlights
- ➤RYONCIL net revenue $28 million, up 44% versus prior year period
- ➤Operating cash spend $2.1 million, down 86% from prior year
- ➤MSB-DR004 Phase 3 chronic low back pain trial completed patient treatment
- ➤FDA confirmed BLA filing may proceed for LVAD-associated GI bleeding
- ➤Cash balance $99 million at September 30, 2026
Expert Statements
Silviu Itescu, Chief Executive of Mesoblast
“Our first-quarter results show continued momentum for Ryoncil(®) (remestemcel-L-rknd) sales. Importantly, we have shown substantial improvement in our net operating cash spend while continuing to advance our strategic objectives for rexlemestrocel-L in chronic pain and cardiovascular diseases”
NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided its activity report for the first fiscal quarter ended September 30, 2026.
Financial highlights included 44% increase in net revenues and 86% improvement in net operational cash spend compared with the prior year period. Operational highlights included completion of all patients treated in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for inflammatory chronic low back pain (CLBP) and a positive meeting with U.S. Food and Drug Administration (FDA) regarding the planned Biologics License Application (BLA) filing for rexlemestrocel-L in prevention of life-threatening gastrointestinal (GI) bleeding in end-stage heart failure patients with a left ventricular assist device (LVAD).
Get started
Create a free account to read the full story.